While the report of biologically inactive carbocyclic thymidine (**1**) in 1962[@b0005] introduced a new class of nucleosides, it was the synthesis of racemic carbocyclic adenosine (aristeromycin, **2**)[@b0010] and subsequent isolation of the (−)-enantiomer from *Streptomyces citricolor* [@b0015] that the era of carbocyclic nucleosides began and became a focal point for the pursuit of carbocyclic nucleosides as therapeutic candidates and as probes for biological processes.[@b0020] Our interest in aristeromycin and analogs therefrom began with the report of 5′-noraristeromycin (**3**) with activity towards human cytomegalovirus.[@b0025] Over the years[@b0030] since 1992 we have looked back to see what analogs lie in the wake of our work that suggested a further look into structural possibilities. Recently, in that regard, we were drawn to our reports that 5′-methylaristeromycin (**4**)[@b0035] and 5′-homoaristeromycin (**5**)[@b0040] have meaningful antiviral properties that had not been developed through analog design. This stimulated us to consider combining the two side chain features of **4** and **5** into diastereomers **6** and **7** (whose designation is derived from 5′-homoaristeromycin in blue possessing a 5′-hydroxyl). The outcome of that pursuit is presented here (see [Fig. 1](#f0005){ref-type="fig"} ).Fig. 1Relevant carbocyclic nucleosides.

Oxidation of alkenes to glycols is well established in the synthetic organic toolbox. Thus, for this investigation, the known N-6 protected carbocyclic adenine nucleoside with the unsaturated C-4′ side chain **8** (available from D-ribose)[@b0045] served as the starting point. To achieve the requisite diastereomers **9a** and **9b** ADmix-α (for **9a**) and ADmix-β (for **9b**) were employed, respectively. Deprotection of **9a** and **9b** with 2 N hydrochloric acid produced **6** and **7**. The stereochemistry of **6** and **7** was determined by mesylation of **9a**/**9b** to **10a**/**10b** that were deprotected to **11a**/**11b**. Reductive removal of the 6′-mesylate with lithium aluminum hydride yielded **12a**/**12b** (a convenient, alternative synthesis of those diastereomers). The spectroscopic properties of **12a** were identical to that previously reported for **4** (same as **12a**).[@b0035] To address any possible structural ambiguity in this study, confirmation of **6** was achieved by an X-ray structural analysis.[@b0050]

In an antiviral analysis,[@b0055] both **6** and **7** showed moderate activity towards hepatitis B (EC~50~ 7.1 μM and 7.4 μM, respectively; CC~50~ \>100 μM)) while only **7** was potent against human cytomegalovirus (EC~50~ 0.72 μM; CC~50~ \>300 μM). Compound **6** was found to lack the significant yellow fever properties reported for **4** indicating addition of a hydroxyl to the methyl carbon of **4** (**12a**), resulted in an undesirable outcome for future development of **4** as a yellow fever antiviral candidate. A similar conclusion can be reached for the loss of the orthopox activity of **5** due to the presence of the extra hydroxyl group on the C-5′ position of both diastereomers **6** and **7** (see [Scheme 1.](#f0010){ref-type="fig"} ).Scheme 1Synthetic steps to targets **6** and **7**. Reagents and conditions: *(a)* ADmix-α for **9a**; ADmix-β for **9b**, *t*-butyl alcohol, H~2~O, 67% for **9a**; 79% for **9b**; *(b)* 2 N HCl, MeOH, 93% for **6**, 86% for **7**; *(c)* MsCl, Et~3~N, CH~2~Cl~2~, 80% for **10a**, 78% for **10b**; *(d)* 2 N HCl, MeOH, 79% for **11a**, 78% for **11b**; *(e)* LiAlH~4~, THF, 89% for **12a**, 90% for **12b**.

In an antiviral analysis,[@b0055] both **6** and **7** showed moderate activity towards hepatitis B (EC~50~ 7.1 μM and 7.4 μM, respectively; CC~50~ \>100 μM)) while only **7** was potent against human cytomegalovirus (EC~50~ 0.72 μM; CC~50~ \>300 μM). Compound **6** was found to lack the significant yellow fever properties reported for **4** indicating addition of a hydroxyl to the methyl carbon of **4** (**12a**), resulted in an undesirable outcome for future development of **4** as a yellow fever antiviral candidate. A similar conclusion can be reached for the loss of the orthopox activity of **5** due to the presence of the extra hydroxyl group on the C-5′ position of both diastereomers **6** and **7**.

Compounds **6** and **7** were inactive towards polio virus, SARS coronavirus, respiratory syncytial virus, hepatitis C virus, herpes simplex 1 and 2 viruses, vaccinia virus, dengue, Rift Valley fever, Venezuelan equine encephalitis, H1N1 influenza A virus, and West Nile virus. No cytotoxicity was found for either **6** or **7** in the assays conducted.

In conclusion, a convenient synthesis of the diastereomeric hybridization of 5′-methylaristeromycin (**4**) and 5′-homoaristeromycin (**5**) to 5′-hydroxy-5′-homoaristeromycin (**6** and **7**) has provided a new C-4′ structural entity for the aristeromycin family of analogs that showed potent HBV (**6** and **7**) and moderate HCMV activities (**7**). It should be noted that the hydroxyl substituents offer the opportunity of making substituent changes at those centers for possible new aristeromycin structural variations.
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